Sarepta Therapeutics faces safety concerns and market uncertainty after patient death

From Financial Modeling Prep: 2025-06-16 16:00:00

Sarepta Therapeutics, a biotech company known for its work on therapies for Duchenne muscular dystrophy, faces competition in the gene therapy space. On June 15, 2025, BMO Capital downgraded Sarepta to a “Market Perform” rating due to safety concerns related to its Elevidys gene therapy, linked to a patient’s death.

Sarepta’s CEO has halted dosing and paused trials after the tragic event, causing the stock to drop 43.92% to $20.29. Investor uncertainty is reflected in the stock’s fluctuation between $18.30 and $21.55. With a market capitalization of $1.99 billion and high trading volume, Sarepta’s future is uncertain.

The recent patient death from liver failure has cast doubt on Elevidys’ development and approval prospects, overshadowing its potential. Sarepta’s stock, once valued at $173.25, faces challenges ahead as it navigates safety concerns and their impact on its gene therapy pipeline.



Read more at Financial Modeling Prep:: Sarepta Therapeutics Faces Challenges Amid Safety …